Skip to Content

Vincasar PFS (vincristine) Disease Interactions

There is 1 disease interaction with Vincasar PFS (vincristine):


Vincristine (Includes Vincasar PFS) ↔ neurologic dysfunction

Severe Potential Hazard, High plausibility. Applies to: Neurologic Disorder, Peripheral Neuropathy

The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome. Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential. Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported. Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy. Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.


  1. Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973): 699-702
  2. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993): 23-7
  3. Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972): 1369-70
  4. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  5. Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992): 370-3
  6. Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973): 782-3
  7. Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992): 1260-2
  8. Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978): 610-2
  9. Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985): 637
  10. Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974): 733-7
  11. Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982): 1285-8
  12. Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973): 1312
View all 12 references

Vincasar PFS (vincristine) drug interactions

There are 323 drug interactions with Vincasar PFS (vincristine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.